Alnylam Pharmaceuticals IncALNY
ASignal's systematic analysis rates ALNY as Neutral.
Reflects the latest available analysis · analyzed Aug 22, 2026
The case on ALNY
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (66.9% YoY)
- High gross margin (79.65%) indicating pricing power
- Positive free cash flow ($271.54M)
- Return on equity of 96.56% reflects exceptional capital efficiency
- Current price near upper end of Bollinger Bands with positive momentum
- MACD histogram expanding above signal line, indicating strengthening uptrend
- Debt-to-equity ratio of 2.21x is elevated
- Forward P/E of 18.77x and PEG ratio of 0.45x suggest potential overvaluation relative to growth
- Missing earnings growth data (N/A)
- No Reddit mentions, indicating low retail investor interest or potential data gap
- SMA50 (266.65) significantly above current price, indicating medium-term downtrend
See the full verdict on ALNY
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ALNY
Most investors never get a second opinion, let alone several. ASignal runs ALNY past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.